WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024.

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

Featured here, the Balance Sheet for Apellis Pharmaceuticals Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...